<--> SHORE-C: Sussex Health Outcomes Research and Education in Cancer


S Catt, R Starkings, V Shilling, L Fallowfield. Patient-reported outcome measures of the impact of cancer on patients’ everyday lives: a systematic review. Journal of Cancer Survivorship 2017, 11:2; 211-232. epublished ahead of print 10 November 2016.

D Rea, A Francis, J Thomas, J Bartlett, S Bowden, D Dodwell, L Fallowfield, C Gaunt, A Hanby, V Jenkins, L Matthews, S Pinder, S Pirrie, M Reed, M Wallis, M Wilcox and J Young on behalf of the LORIS Trial Management Group.  Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial. Annals of Surgical Oncology online, Letters to the Editor.

F Cardoso, A Costa, E Senkus, M Aapro, F Andre, C H Barrios, J Bergh, G Bhattacharyya, L Biganzoli, M J Cardoso, L Carey, D Corneliussen-James, G. Curigliano, V Dieras, N El Saghir, A Eniu, L Fallowfield, D Fenech, P Francis, K Gelmon, A Gennari, N Harbeck, C Hudis, B Kaufman, I Krop, M Mayer, H Meijer, S Mertz, S Ohno, O Pagani, E Papadopoulos, F Peccatori, F Pernault-Llorca, M J Piccart, J Y Pierga, H Rugo, L Shockney, G Sledge, S Swain, C Thomssen, A Tutt, D Vorobiof, B Xu, L Norton & E Winer.  3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC3). Simultaneously e-published 5th Dec 2016 in Annals of Oncology & The Breast.

E Vrdoljak, N Marschner, C Zielinski, J Gligorov, J Cortes, F Puglisi, M Aapro, L Fallowfield, A Fontana, M Inbar, Z Kahan, A Welt, C Lévy, E Brain, X Pivot, C Putzu, A González Martín, S de Ducla, V Easton & G von Minckwitz. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Annals of Oncology, 27:2046-2051. epublished ahead of print 8 August 2016.

F A da Costa, M C Ribeiro, S Braga, E Carvalho, F Francisco, A Da Costa Miranda, A Moreira, L Fallowfield.  Sexual dysfunction in breast cancer survivors: cross-cultural adaptation of the Sexual Activity Questionnaire for use in Portugal. Acta Médica Portuguesa 2016 Sep;29(9):533-541

Rugo HS, Rumble B, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston RD, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ. Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. Journal of Clinical Oncology, 2016, 34(25): 3069-3104.
epublished ahead of print 23 May 2016

Fallowfield LJ, Catt SL, May SF, Matthews L, Shilling VM, Simcock R, Westwell S, Jenkins VA. Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits. Supportive Care in Cancer, 2017, 15:237-244. epublished ahead of print 13 Sept 2016

Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY.  Ovarian cancer.  Nature Reviews Disease Primers. E-published with restricted access 25 August 2016, 2:16061.  DOI 10.1038/nrdp.2016.61

Jenkins V, Fallowfield L. No man’s land: information needs and resources of men with metastatic castrate resistant prostate cancer. Supportive Care in Cancer, 2016, 24(11);4471-4473

Fallowfield L, Payne H, Jenkins V.  Patient-reported outcomes in metastatic castration-resistant prostate cancer. Nature Reviews Clinical Oncology, 2016, 13:643-650.

Gibbons E, Black N, Fallowfield L, Newhouse R, Fitzpatrick R. Patient-reported outcome measures and the evaluation of services. In Raine R, Fitzpatrick R, Barratt H, Bevan G, Black N, Boaden R, et al. Essay 4. Patient-reported outcome measures and the evaluation of services, in Challenges, solutions and future directions in the evaluation of service innovations in health care and public health. Health Services and Delivery Research 2016;4(16). pp. 55–68.

Madden L, Shilling V, Woolfall K, Sowden E, Smyth RL, Williamson PR, et al. Questioning assent: how are children's views included as families make decisions about clinical trials? Child: Care, Health and Development. 2016  epublished ahead of print 27 March 2016 . 

Jenkins V, Thwaites R, Cercignani M, Sacre S, Harrison N, Whiteley‑Jones H, Mullen L, Chamberlain G, Davies K, Zammit C, Matthews L & Helena Harder H. A feasibility study exploring the role of pre-operative assessment when examining the mechanism of ‘chemo-brain’ in breast cancer patients. SpringerPlus, 2016, 5:390

Jenkins V, May S. Stress levels amongst nurses caring for women with breast cancer: results from a survey of nurses on the South East Coast. Association of Breast Surgery Handbook 2016, 69-72. Available to ABS members only.

Shillling V, Matthews L, Jenkins J, Fallowfield L.  Patient-reported outcome measures for cancer caregivers: a systematic review.  Quality of Life Research 2016, 25(8):1859-1876.

Paluch-Shimon S, Pagani O, Partridge AH, Bar-Meir E,  Fallowfield L, Fenlon D, Friedman E, Gelmon K, Gentilini O, Geraghty J, Harbeck N, Higgins S, Loibl S, Moser E, Peccatori F, Raanani H, Kaufman B, Cardoso F. Second international consensus guidelines for breast cancer in young women (BCY2).  The Breast, 2016;26:87-99.

Menon U , Kalsi JK , Gentry-Maharaj A , Ryan A , Burnell M , Parmar M , Fallowfield L , Campbell S , McGuire A , Skates S ,Jacobs I.  Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al. Journal of Clinical Oncology 2016, 34(2):201-202.  First published online November 2015

Fallowfield L, Francis A. Overtreatment of Low-Grade Ductal Carcinoma In Situ. JAMA Oncology 2016;2(3):382-383. First published online 23 December 2015

Nikapota AD, Cresswell J, Appleyard S, Catt SL QoL after Bladder Cancer: A Prospective Study Comparing Patient-related Outcomes after Radical Surgery or Radical Radiotherapy for Bladder Cancer. Clinical Oncology. First published on line 30 December 2015

^ Top